Accuracy of TNM staging in colorectal cancer: A review of current culprits, the modern role of morphology and stepping-stones for improvements in the molecular era

Scandinavian Journal of Gastroenterology

Volumn 49, Issue 10, 2014, Pages 1153-1163

  Lea, Dordi ^a   Haland, Sven ^a   Hagland, Hanne R ^a   Soreide, Kjetil ^a,b  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

Author keywords

Cancer staging; Colorectal carcinoma; Histopathology; Immunoscore; Tumor node metastases

Indexed keywords

ANGIOGENESIS; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; COLORECTAL CANCER; DIAGNOSTIC ACCURACY; DISEASE COURSE; DISEASE FREE SURVIVAL; DISTANT METASTASIS; EPITHELIAL MESENCHYMAL TRANSITION; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; LYMPH NODE METASTASIS; OVERALL SURVIVAL; REPRODUCIBILITY; REVIEW; SURVIVAL RATE; SURVIVAL TIME; TUMOR DIFFERENTIATION; TUMOR MICROENVIRONMENT; COLORECTAL TUMOR; IMMUNOLOGY; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PROCEDURES; VASCULARIZATION;

COLORECTAL NEOPLASMS; HUMANS; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; TUMOR MICROENVIRONMENT;

EID: 84907229394     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2014.950692     Document Type: Review

References (117)

1. Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, et al. Colorectal cancer. Lancet 2010;375: 1030-47.
2. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB. Cancer incidence in five continents. Volume VIII. IARC Sci Publ 2002:1-781.
3. Center MM, Jemal A, Smith RA, Ward E. Worldwide variations in colorectal cancer. CA Cancer J Clin 2009;59: 366-78.
4. Kodeda K, Nathanaelsson L, Jung B, Olsson H, Jestin P, Sjovall A, et al. Population-based data from the Swedish Colon Cancer Registry. Br J Surg 2013;100:1100-7.
5. Nedrebø BS, Søreide K, Eriksen MT, Dørum LM, Kvaloy JT, Soreide JA, et al. Survival effect of implementing national treatment strategies for curatively resected colonic and rectal cancer. Br J Surg 2011;98:716-23.
6. Casado-Saenz E, Feliu J, Gomez-Espana MA, Sanchez-Gastaldo A, Garcia-Carbonero R. SEOM Clinical guidelines for the treatment of advanced colorectal cancer 2013. Clin Transl Oncol 2013;15:996-1003.
7. Ohlsson B, Stenram U, Tranberg KG. Resection of colorectal liver metastases: 25-year experience. World J Surg 1998; 22:268-76; discussion 76-7.
8. de Jong MC, Pulitano C, Ribero D, Strub J, Mentha G, Schulick RD, et al. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: An international multi-institutional analysis of 1669 patients. Ann Surg 2009;250:440-8.
9. Bretthauer M, Kalager M. Principles, effectiveness and caveats in screening for cancer. Br J Surg 2013;100:55-65.
10. Garborg K, Holme O, Loberg M, Kalager M, Adami HO, Bretthauer M. Current status of screening for colorectal cancer. Ann Oncol 2013;24:1963-72.
11. Sorbin LH, Gospodarowicz MK, Wittekind C. International UnionagainstCancer(UICC).TNMclassificationofmalignant tumours. 7 edition.West Sussex, UK:Wiley-Blackwell; 2009.
12. Cascinu S, Staccioli MP, Gasparini G, Giordani P, Catalano V, Ghiselli R, et al. Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer. Clin Cancer Res 2000;6:2803-7.
13. Gonen M, Weiser MR. Whither TNM? Semin Oncol 2010; 37:27-30.
14. Ueno H, Mochizuki H, Akagi Y, Kusumi T, Yamada K, Ikegami M, et al. Optimal colorectal cancer staging criteria in TNM classification. J Clin Oncol 2012;30:1519-26.
15. Williams ST, Beart Jr. R.W. Staging of colorectal cancer. Semin Surg Oncol 1992;8:89-93.
16. Hashiguchi Y, Hase K, Kotake K, Ueno H, Shinto E, Mochizuki H, et al. Evaluation of the seventh edition of the tumour, node, metastasis (TNM) classification for colon cancer in two nationwide registries of the United States and Japan. Colorectal Dis 2012;14:1065-74.
17. Puppa G, Sonzogni A, Colombari R, Pelosi G. TNM staging system of colorectal carcinoma: A critical appraisal of challenging issues. Arch Pathol Lab Med 2010;134:837-52.
18. Nagtegaal ID, Quirke P, Schmoll HJ. Has the new TNM classification for colorectal cancer improved care? Nat Rev Clin Oncol 2012;9:119-23.
19. Veen T, Nedrebø BS, Stormark K, Søreide JA, Kørner H, Søreide K. Qualitative and quantitative issues of lymph nodes as prognostic factor in colon cancer. Dig Surg 2013;30:1-11.
20. Gunderson LL, Jessup JM, Sargent DJ, Greene FL, Stewart AK. Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol 2010;28:264-71.
21. American Joint Committee on Cancer. Cancer staging manual. 7 edition. Chicago, IL: Springer; 2010. p 649.
22. Lan YT, Yang SH, Chang SC, Liang WY, Li AF, Wang HS, et al. Analysis of the seventh edition of American Joint Committee on colon cancer staging. Int J Colorectal Dis 2012;27:657-63.
23. Sorbin LH, Fleming ID. TNM classification of malignant tumours. New York: Wiley; 1997.
24. Sorbin LH, Wittekind Ch. TNM classification of malignant tumours. New York: Wiley; 2002.
25. Lorenzon L, Pilozzi E, La Torre M, Ziparo V, Ferri M. Impact and prognostic implications of colon cancers stage II sub-classification through the years. Int J Colorectal Dis 2012;27:1311-18.
26. Snaebjornsson P, Coupe VM, Jonasson L, Meijer GA, van Grieken NC, Jonasson JG. pT4 stage II and III colon cancers carry the worst prognosis in a nationwide survival analysis. Shepherd's local peritoneal involvement revisited. Int J Cancer 2014;135:467-78.
27. Stewart CJ, Hillery S, Platell C, Puppa G. Assessment of serosal invasion and criteria for the classification of pathological (p) T4 staging in colorectal carcinoma: Confusions, controversies and criticisms. Cancers (Basel) 2011;3:164-81.
28. Compton C, Fenoglio-Preiser CM, Pettigrew N, Fielding LP. American joint committee on cancer prognostic factors consensus conference: Colorectal workinggroup.Cancer2000;88: 1739-57.
29. Oh SY, Kim YB, Paek OJ, Suh KW. Contiguous invasion per se does not affect prognosis in colon cancer. J Surg Oncol 2009;99:71-4.
30. Compton CC. Key issues in reporting common cancer specimens: Problems in pathologic staging of colon cancer. Arch Pathol Lab Med 2006;130:318-24.
31. Nagtegaal ID, Quirke P. Colorectal tumour deposits in the mesorectum and pericolon; a critical review. Histopathology 2007;51:141-9.
32. Goldstein NS, Turner JR. Pericolonic tumor deposits in patients with T3N+MO colon adenocarcinomas: Markers of reduced disease free survival and intra-Abdominal metastases and their implications for TNM classification. Cancer 2000;88:2228-38.
33. Wunsch K, Muller J, Jahnig H, Herrmann RA, Arnholdt HM, Markl B. Shape is not associated with the origin of pericolonic tumor deposits. Am J Clin Pathol 2010; 133:388-94.
34. Nagtegaal ID, Tot T, Jayne DG, McShane P, Nihlberg A, Marshall HC, et al. Lymph nodes, tumor deposits, and TNM: Are we getting better? J Clin Oncol 2011;29:2487-92.
35. Edge SBB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. editors. AJCC cancer staging manual. New York: Springer; 2010. pp 649.
36. Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO classification of tumours of the digestive system. Lyon: International Agency for Research on Cancer; 2010.
37. Rock JB, Washington MK, Adsay NV, Greenson JK, Montgomery EA, Robert ME, et al. Debating deposits: An interobserver variability study of lymph nodes and pericolonic tumor deposits in colonic adenocarcinoma. Arch Pathol Lab Med 2014;138:636-42.
38. Song YX, Gao P, Wang ZN, Liang JW, Sun Z, Wang MX, et al. Can the tumor deposits be counted as metastatic lymph nodes in the UICC TNM staging system for colorectal cancer? PLoS One 2012;7:e34087.
39. Puppa G. Enhanced pathologic analysis for pericolonic tumor deposits: Is it worth it? Am J Clin Pathol 2010;134: 1019-21.
40. Lin Y, Chappell R, Gonen M. A systematic selection method for the development of cancer staging systems. Stat Methods Med Res 2013; [Epub ahead of print].
41. Quirke P, Palmer T, Hutchins GG, West NP. Histopathological work-up of resection specimens, local excisions and biopsies in colorectal cancer. Dig Dis 2012;30:2-8.
42. Quirke P, Cuvelier C, Ensari A, Glimelius B, Laurberg S, Ortiz H, et al. Evidence-based medicine: The time has come to set standards for staging. J Pathol 2010; 221:357-60.
43. Sobin LH, Compton CA, Gospodarowicz M, Greene FL, Gunderson LL, Jessup JM, et al. 'Evidence-based medicine: The time has come to set standards for staging'. Is a radical overhaul really needed? J Pathol 2010;221:361-2.
44. Blenkinsopp WK, Stewart-Brown S, Blesovsky L, Kearney G, Fielding LP. Histopathology reporting in large bowel cancer. J Clin Pathol 1981;34:509-13.
45. Boyle P, Levin B. World cancer report. Lyon: IARC Press; 2008.
46. Benedix F, Kuester D, Meyer F, Lippert H. [Influence of mucinous and signet-ring cell differentiation on epidemiological, histological, molecular biological features, and outcome in patients with colorectal carcinoma]. Zentralbl Chir 2013;138:427-33.
47. Nitsche U, Zimmermann A, Spath C, Muller T, Maak M, Schuster T, et al. Mucinous and signet-ring cell colorectal cancers differ from classical adenocarcinomas in tumor biology and prognosis. Ann Surg 2013;258:775-83.
48. Sung CO, Seo JW, Kim KM, Do IG, Kim SW, Park CK. Clinical significance of signet-ring cells in colorectal mucinous adenocarcinoma. Mod Pathol 2008;21:1533-41.
49. Lee HJ, Eom DW, Kang GH, Han SH, Cheon GJ, Oh HS, et al. Colorectal micropapillary carcinomas are associated with poor prognosis and enriched in markers of stem cells. Mod Pathol 2013;26:1123-31.
50. Lino-Silva LS, Salcedo-Hernandez RA, Caro-Sanchez CH. Colonic micropapillary carcinoma, a recently recognized subtype associated with histological adverse factors: Clinicopathological analysis of 15 cases. Colorectal Dis 2012;14: E567-72.
51. Dukes C. Histological grading of rectal cancer: (section of pathology). Proc R Soc Med 1937;30:371-6.
52. Grinnell RS. The grading and prognosis of carcinoma of the colon and rectum. Ann Surg 1939;109:500-33.
53. Ueno H, Kajiwara Y, Shimazaki H, Shinto E, Hashiguchi Y, Nakanishi K, et al. New criteria for histologic grading of colorectal cancer. Am J Surg Pathol 2012;36:193-201.
54. Greene FL, Stewart AK, Norton HJ. A new TNM staging strategy for node-positive (stage III) colon cancer: An analysis of 50,042 patients. Ann Surg 2002;236:416-21; discussion 21.
55. Freedman LS, Macaskill P, Smith AN. Multivariate analysis of prognostic factors for operable rectal cancer. Lancet 1984; 2:733-6.
56. Thomas GD, Dixon MF, Smeeton NC, Williams NS. Observer variation in the histological grading of rectal carcinoma. J Clin Pathol 1983;36:385-91.
57. Quirke P, Morris E. Reporting colorectal cancer. Histopathology 2007;50:103-12.
58. Liang P, Nakada I, Hong JW, Tabuchi T, Motohashi G, Takemura A, et al. Prognostic significance of immunohistochemically detected blood and lymphatic vessel invasion in colorectal carcinoma: Its impact on prognosis. Ann Surg Oncol 2007;14:470-7.
59. Bentzen SM, Balslev I, Pedersen M, Teglbjaerg PS, Hanberg-Sorensen F, Bone J, et al. Time to loco-regional recurrence after resection of Dukes' B and C colorectal cancer with or without adjuvant postoperative radiotherapy. A multivariate regression analysis. Br J Cancer 1992;65: 102-7.
60. Puppa G, Caneva A, Colombari R. Venous invasion detection in colorectal cancer: Which approach, which technique? J Clin Pathol 2009;62:102-3.
61. Sternberg A, Amar M, Alfici R, Groisman G. Conclusions from a study of venous invasion in stage IV colorectal adenocarcinoma. J Clin Pathol 2002;55:17-21.
62. Ueno H, Price AB, Wilkinson KH, Jass JR, Mochizuki H, Talbot IC. A new prognostic staging system for rectal cancer. Ann Surg 2004;240:832-9.
63. Lugli A, Karamitopoulou E, Zlobec I. Tumour budding: A promising parameter in colorectal cancer. Br J Cancer 2012;106:1713-17.
64. Jass JR, O'Brien J, Riddell RH, Snover DC. Recommendations for the reporting of surgically resected specimens of colorectal carcinoma: Association of Directors of Anatomic and Surgical Pathology. Am J Clin Pathol 2008;129:13-23.
65. Hase K, Shatney C, Johnson D, Trollope M, Vierra M. Prognostic value of tumor "budding" in patients with colorectal cancer. Dis Colon Rectum 1993;36:627-35.
66. Kazama S, Watanabe T, Ajioka Y, Kanazawa T, Nagawa H. Tumour budding at the deepest invasive margin correlates with lymph node metastasis in submucosal colorectal cancer detected by anticytokeratin antibody CAM5.2. Br J Cancer 2006;94:293-8.
67. Nakamura T, Mitomi H, Kikuchi S, Ohtani Y, Sato K. Evaluation of the usefulness of tumor budding on the prediction of metastasis to the lung and liver after curative excision of colorectal cancer. Hepatogastroenterology 2005;52:1432-5.
68. Wang LM, Kevans D, Mulcahy H, O'Sullivan J, Fennelly D, Hyland J, et al. Tumor budding is a strong and reproducible prognostic marker in T3N0 colorectal cancer. Am J Surg Pathol 2009;33:134-41.
69. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: Links to genetic instability. Carcinogenesis 2009;30: 1073-81.
70. Di Caro G, Bergomas F, Grizzi F, Doni A, Bianchi P, Malesci A, et al. Occurrence of tertiary lymphoid tissue is associated with T-cell infiltration and predicts better prognosis in early-stage colorectal cancers. Clin Cancer Res 2014; 20:2147-58.
71. Roxburgh CS, McMillan DC. The role of the in situ local inflammatory response in predicting recurrence and survival in patients with primary operable colorectal cancer. Cancer Treat Rev 2012;38:451-66.
72. Curtis NJ, Primrose JN, Thomas GJ, Mirnezami AH, Ottensmeier CH. The adaptive immune response to colorectal cancer: From the laboratory to clinical practice. Eur J Surg Oncol 2012;38:889-96.
73. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313:1960-4.
74. Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T, et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 2011;29:610-18.
75. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008;454:436-44.
76. Chaput N, Svrcek M, Auperin A, Locher C, Drusch F, Malka D, et al. Tumour-infiltrating CD68+ and CD57+ cells predict patient outcome in stage II-III colorectal cancer. Br J Cancer 2013;109:1013-22.
77. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003;4:330-6.
78. Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 2003;9:606-12.
79. Loddenkemper C, Schernus M, Noutsias M, Stein H, Thiel E, Nagorsen D. In situ analysis of FOXP3+ regulatory T cells in human colorectal cancer. J Transl Med 2006;4:52.
80. Kim M, Grimmig T, Grimm M, Lazariotou M, Meier E, Rosenwald A, et al. Expression of Foxp3 in colorectal cancer but not in Treg cells correlates with disease progression in patients with colorectal cancer. PLoS One 2013;8: E53630.
81. Galon J, Franck P, Marincola FM, Angell HK, Thurin M, Lugli A, et al. Cancer classification using the Immunoscore: A worldwide task force. J Transl Med 2012;10:205.
82. Pages F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, Bindea G, et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol 2009;27:5944-51.
83. Anitei MG, Zeitoun G, Mlecnik B, Marliot F, Haicheur N, Todosi AM, et al. Prognostic and predictive values of the immunoscore in patients with rectal cancer. Clin Cancer Res 2014;20:1891-9.
84. Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, et al. Towards the introduction of the "Immunoscore" in the classification of malignant tumours. J Pathol 2014;232:199-209.
85. Huijbers A, Tollenaar RA, v Pelt GW, Zeestraten EC, Dutton S, McConkey CC, et al. The proportion of tumorstroma as a strong prognosticator for stage II and III colon cancer patients: Validation in the VICTOR trial. Ann Oncol 2013;24:179-85.
86. Perez-Villamil B, Romera-Lopez A, Hernandez-Prieto S, Lopez-Campos G, Calles A, Lopez-Asenjo JA, et al. Colon cancer molecular subtypes identified by expression profiling and associated to stroma, mucinous type and different clinical behavior. BMC Cancer 2012;12:260.
87. Wikberg ML, Edin S, Lundberg IV, Van Guelpen B, Dahlin AM, Rutegard J, et al. High intratumoral expression of fibroblast activation protein (FAP) in colon cancer is associated with poorer patient prognosis. Tumour Biol 2013;34:1013-20.
88. Saadi A, Shannon NB, Lao-Sirieix P, O'Donovan M, Walker E, Clemons NJ, et al. Stromal genes discriminate preinvasive from invasive disease, predict outcome, and highlight inflammatory pathways in digestive cancers. Proc Natl Acad Sci USA 2010;107:2177-82.
89. Inafuku Y, Furuhata T, Tayama M, Okita K, Nishidate T, Mizuguchi T, et al. Matrix metalloproteinase-2 expression in stromal tissues is a consistent prognostic factor in stage II colon cancer. Cancer Sci 2009;100:852-8.
90. Henry LR, Lee HO, Lee JS, Klein-Szanto A, Watts P, Ross EA, et al. Clinical implications of fibroblast activation protein in patients with colon cancer. Clin Cancer Res 2007; 13:1736-41.
91. He X, Chen Z, Jia M, Zhao X. Downregulated e-cadherin expression indicates worse prognosis in asian patients with colorectal cancer: Evidence from meta-Analysis. PLoS One 2013;8:e70858.
92. Roepman P, Schlicker A, Tabernero J, Majewski I, Tian S, Moreno V, et al. Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-To-mesenchymal transition. Int J Cancer 2014; 134:552-62.
93. De Sousa EMF, Wang X, Jansen M, Fessler E, Trinh A, de Rooij LP, et al. Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nat Med 2013;19:614-18.
94. Peddareddigari VG, Wang D, Dubois RN. The tumor microenvironment in colorectal carcinogenesis. Cancer Microenviron 2010;3:149-66.
95. Zhang QW, Liu L, Gong CY, Shi HS, Zeng YH, Wang XZ, et al. Prognostic significance of tumor-Associated macrophages in solid tumor: A meta-Analysis of the literature. PLoS One 2012;7:e50946.
96. Cronier L, Crespin S, Strale PO, Defamie N, Mesnil M. Gap junctions and cancer: New functions for an old story. Antioxid Redox Signal 2009;11:323-38.
97. Han Y, Zhang PJ, Chen T, Yum SW, Pasha T, Furth EE. Connexin43 expression increases in the epithelium and stroma along the colonic neoplastic progression pathway: Implications for its oncogenic role. Gastroenterol Res Pract 2011;2011:561719.
98. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008;358: 2039-49.
99. GayaA,TseV.Apreclinicalandclinicalreviewofaflibercept for themanagement ofcancer.CancerTreatRev2012;38:484-93.
100. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011;144:646-74.
101. Mathonnet M, Perraud A, Christou N, Akil H, Melin C, Battu S, et al. Hallmarks in colorectal cancer: Angiogenesis and cancer stem-like cells. World J Gastroenterol 2014;20: 4189-96.
102. Choi HJ, Hyun MS, Jung GJ, Kim SS, Hong SH. Tumor angiogenesis as a prognostic predictor in colorectal carcinoma with special reference to mode of metastasis and recurrence. Oncology 1998;55:575-81.
103. Des Guetz G, Uzzan B, Nicolas P, Cucherat M, Morere JF, Benamouzig R, et al. Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-Analysis of the literature. Br J Cancer 2006;94:1823-32.
104. Lee JC, Chow NH, Wang ST, Huang SM. Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur J Cancer 2000;36:748-53.
105. Kaio E, Tanaka S, Kitadai Y, Sumii M, Yoshihara M, Haruma K, et al. Clinical significance of angiogenic factor expression at the deepest invasive site of advanced colorectal carcinoma. Oncology 2003;64:61-73.
106. Tayama M, Furuhata T, Inafuku Y, Okita K, Nishidate T, Mizuguchi T, et al. Vascular endothelial growth factor 165b expression in stromal cells and colorectal cancer. World J Gastroenterol 2011;17:4867-74.
107. Kazama S, Watanabe T, Kanazawa T, Hatano K, Nagawa H. Vascular endothelial growth factor-C (VEGFC) is a more specific risk factor for lymph node metastasis than VEGF-D in submucosal colorectal cancer. Hepatogastroenterology 2007;54:71-6.
108. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8.
109. Hansen TF, Sorensen FB, Spindler KL, Olsen DA, Andersen RF, Lindebjerg J, et al. Microvessel density and the association with single nucleotide polymorphisms of the vascular endothelial growth factor receptor 2 in patients with colorectal cancer. Virchows Arch 2010;456: 251-60.
110. Lindmark G, Gerdin B, Sundberg C, Pahlman L, Bergstrom R, Glimelius B. Prognostic significance of the microvascular count in colorectal cancer. J Clin Oncol 1996;14:461-6.
111. Sheehan KM, Steele C, Sheahan K, O'Grady A, Leader MB, Murray FE, et al. Association between cyclooxygenase-2-expressing macrophages, ulceration and microvessel density in colorectal cancer. Histopathology 2005;46:287-95.
112. Rajaganeshan R, Prasad R, Guillou PJ, Chalmers CR, Scott N, Sarkar R, et al. The influence of invasive growth pattern and microvessel density on prognosis in colorectal cancer and colorectal liver metastases. Br J Cancer 2007;96: 1112-17.
113. Pietra N, Sarli L, Caruana P, Cabras A, Costi R, Gobbi S, et al. Is tumour angiogenesis a prognostic factor in patients with colorectal cancer and no involved nodes? Eur J Surg 2000;166:552-6.
114. Uribarrena AR, Ortego J, Fuentes J, Raventos N, Parra P, Uribarrena ER. Prognostic value of microvascular density in dukes a and B (t1-T4, n0, m0) colorectal carcinomas. Gastroenterol Res Pract 2009;2009:679830.
115. Vermeulen PB, Gasparini G, Fox SB, Colpaert C, Marson LP, Gion M, et al. Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur J Cancer 2002;38:1564-79.
116. Mallett S, Timmer A, Sauerbrei W, Altman DG. Reporting of prognostic studies of tumour markers: A review of published articles in relation to REMARK guidelines. Br J Cancer 2010;102:173-80.
117. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. Toward complete and accurate reporting of studies of diagnostic accuracy. The STARD initiative. Am J Clin Pathol 2003;119: 18-22.